Topical timolol in dermatology: infantile haemangiomas and beyond.

Clin Exp Dermatol

Mid Cheshire NHS Foundation Trust, Macclesfield, UK.

Published: May 2022

Timolol, a nonselective β-adrenergic receptor blocker, is well-tolerated and is becoming increasingly popular in dermatology, especially in the management of infantile haemangioma (IH). Its effects are mainly due to vasoconstriction, inhibition of angiogenesis and keratinocyte migration promotion for re-epithelialization and wound healing. We review the evidence behind the use of timolol in several dermatological conditions including IH, pyogenic granulomas, Kaposi sarcoma, chronic wound healing, postsurgical wounds, acne vulgaris, rosacea, eczema and red scrotum syndrome.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.15021DOI Listing

Publication Analysis

Top Keywords

wound healing
8
topical timolol
4
timolol dermatology
4
dermatology infantile
4
infantile haemangiomas
4
haemangiomas timolol
4
timolol nonselective
4
nonselective β-adrenergic
4
β-adrenergic receptor
4
receptor blocker
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!